BDBM235820 US9364459, G

SMILES: COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12

InChI Key: InChIKey=ILDYBWHQYPVFSI-UHFFFAOYSA-O

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 235820   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	129	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair